Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,”
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs.
CrownBio is a leading contract research organization (CRO) in both the drug discovery and biomarker discovery arenas with a range of innovative product portfolios available across sites in Asia, th...
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
